All In Biotech

NDA 050557 · Valeant Intl

Benzamycin

Benzoyl Peroxide, Erythromycin · Topical

Last checked: Nov 19, 2026Latest source record: Dec 5, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Oct 26, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

162

44 Phase 3, 7 recruiting

FAERS reports

162

83 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 30, 2020.

INDICATIONS AND USAGE Benzamycin Topical Gel is indicated for the topical treatment of acne vulgaris.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 26, 1984 Original approval · Type 4 - New Combination
1 products under this application
  • BENZAMYCIN · BENZOYL PEROXIDE 5%; ERYTHROMYCIN 3% · GEL, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Benzoyl Peroxide" as an intervention, any sponsor and status, largest first.

All 162 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective19
  • inflammatory bowel disease18
  • colitis ulcerative15
  • depression14
  • anxiety11
  • product physical consistency issue11
  • colitis10
  • rash10
  • crohn^s disease9
  • off label use9
  • dry skin8
  • irritable bowel syndrome8

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20054
20061
20071
20082
20093
20107
201110
20127
20137
20144
20159
201620
201721
201816
201914
20209
20218
20222
20236
20243
20254
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 363 on PubMed

Sponsor: Valeant Intl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.